Abstract 1297O 32Brahmer J, et al. Five-year follow-up from the CA209- 003 study of nivolumab in previously treated advanced non-small cell lung cancer: clin ical ch aracteristics of long-term survivors. Oral presentation presented at: American Associ ation for Cancer Research (AACR) Annual Meeting; April 1-5, 2017; Washington, DC, USA. 33Felip E et al., Three-year follow-up from Checkmate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small lung cancer (NSCLC). Poster discussion presentation at the European Society of Me dical Oncology Annual Meeting.